Polycystic Kidney Disease 5 C4539903
Polycystic Kidney Disease type 5 is a rare genetic form of PKD involving cyst formation in the kidneys. Management involves regular monitoring, symptom control, and addressing complications as they arise.
Key facts at a glance
- ICD-10
- Q63.9
- ICD-11
- LA00.0
- Body system
- renal
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Changes in urination or swelling
(renal)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Hypertension
(cardiovascular)Flank pain
(renal)Hematuria
(renal)Nephrolithiasis
(renal)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Pain Management Therapy
For pain associated with enlarged polycystic kidneys, treatment may include acetaminophen as first-line therapy, with careful evaluation of cyst infection or hemorrhage as underlying causes before escalating to other analgesics.
Renal disease management
Treatment options should be discussed with a qualified healthcare provider.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Polycystic Kidney Disease 5 C4539903?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bergmann C, Guay-Woodford LM, Harris PC, et al. Polycystic Kidney Disease: KDIGO Clinical Practice Guidelines for the Diagnosis and Management of ADPKD and Related Disorders. Kidney Int. 2022.
Cornec-Le Gall E, Alam A, Perrone RD. Autosomal Dominant Polycystic Kidney Disease. Lancet. 2019.
Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2012.
Liu BT, Ding J, Zhou GJ, et al. Systematic Review and Meta-Analysis of Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2020.
Medication Comparisons
Compare medications used to treat Polycystic Kidney Disease 5 C4539903. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy